At a glance
ClinicalIndex Comparison Record- ✓Confirmed diagnosis of precursor B or T cell lymphoblastic leukemia (L1 or L2 morphology) or acute undifferentiated leukemia
- ✓CD52 ≥10% expression on leukemic blast cells required to receive alemtuzumab
- ✕Burkitt-type ALL (FAB L3 with surface immunoglobulin positivity)
- ✕Prior treatment for leukemia except emergency leukapheresis, hydroxyurea for hyperleukocytosis, or CNS-directed radiation (one dose only)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
In Brief
A Phase 2 clinical trial evaluating allopurinol, cyclophosphamide, and 15 other interventions for Acute Undifferentiated Leukemia and 13 related conditions. Completed, enrolled 302 participants across 1 site.
Detailed Summary
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy also work in different ways to kill cancer cells or stop them from growing. Giving alemtuzumab together with combination chemotherapy may be a better way to block cancer growth.
Study Details
Timeline
Interventions
Given PO
Given IV
Given IV
Given IV
Given PO and as eye drops
Given SC
Given SC
Given PO
Given IT, IV, and PO
Given IV
Given PO
Given PO
Given IV and PO
Given SC
Given PO
Correlative studies
Correlative studies